开发强效和选择性的RIPK1降解剂,针对其非酶功能用于癌症治疗
Zhen Zhang1, Chunrong Li1, Nina J Hawkins1
1Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison Madison, Wisconsin 53705, United States.
向受体相互作用蛋白激酶1 (RIPK1) 降解,而不是抑制,提高了癌症放射治疗的疗效. 一种新的RIPK1降解剂与X射线放射治疗相结合,有效地抑制了瘤生长,显示出新型癌症治疗的前景.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 受体相互作用蛋白激酶1 (RIPK1) 对于免疫反应和细胞死亡至关重要.
- RIPK1的支架功能赋予了对免疫检查点阻塞 (ICB) 的抵抗力,在癌症中呈现出治疗标.
- RIPK1调节了诸如ICB和X射线放射治疗 (XRT) 等免疫刺激疗法的疗效.
研究的目的:
- 调查针对RIPK1降解与XRT结合的治疗潜力.
- 评估一种新的RIPK1降解剂对癌症治疗疗效的评估.
主要方法:
- 开发一种强效和选择性的RIPK1降解剂.
- 在临床前癌症模型中,RIPK1降解剂与X射线放射治疗 (XRT) 的联合治疗.
- 对瘤生长抑制和治疗疗效的评估.
主要成果:
- 与 XRT 结合的 RIPK1 降解剂显著抑制了瘤生长.
- 观察到增强的治疗疗效,没有明显的不良影响.
- 一种RIPK1抑制剂没有显著的治疗效果,突出显示了降解对抑制的重要性.
结论:
- 针对RIPK1降解,特别是其非酶功能,是一种有前途的策略,可以提高放射治疗的结果.
- 降解RIPK1为增强XRT在癌症治疗中的效果提供了一种新的方法.
- 选择性RIPK1降解表明与与XRT结合的RIPK1抑制相比,具有更高的治疗潜力.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Experimental RNAi
Inhibition of Cdk Activity
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
